Anagram Therapeutics's $250M: A Big Biotech Bet Amid AI's Spotlight
Anagram Therapeutics raised $250M in May 2026, one of the largest biotech rounds of the period, proving life-sciences capital is alive alongside AI.
Healthtech venture capital spans digital health platforms, care delivery innovation, diagnostics, and AI-enabled clinical workflows. Our healthtech coverage tracks the funding rounds and fund strategies defining the next generation of healthcare technology.
Browse healthtech venture capital articles below.
Anagram Therapeutics raised $250M in May 2026, one of the largest biotech rounds of the period, proving life-sciences capital is alive alongside AI.
NYC digital health raised $2.4B in H1 2025 (+10% YoY). Life sciences took 27% of NYC venture funding. Here's where the money went and who's writing checks.
Parallel's Paris round highlights Europe's growing confidence in vertical AI agents for regulated industries like healthcare.
Frazier Life Sciences closed Fund XII at over $1.3 billion on July 31, 2025 — one of the largest biotech venture funds closed in July 2025.
Houston-based Modi Ventures closed its oversubscribed second fund at $88 million on July 16, 2025, investing at the intersection of AI, biology, and medical technology.
Junction, now headquartered in New York, announced an $18M funding round on March 11, 2025, to scale infrastructure linking wearable data and lab workflows.